These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22956134)

  • 1. Identification of allosteric inhibitors of p21-activated kinase.
    Viaud J; Peterson JR
    Methods Mol Biol; 2012; 928():67-79. PubMed ID: 22956134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of PAK1 kinase inhibitors with "in silico" modeling methods].
    Ferenc B; Csaba SK; Zoltán G; Jeno M; Zoltán V; György K; László O
    Acta Pharm Hung; 2010; 80(4):155-61. PubMed ID: 21404476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p21-Activated kinase inhibitors: a patent review.
    Crawford JJ; Hoeflich KP; Rudolph J
    Expert Opin Ther Pat; 2012 Mar; 22(3):293-310. PubMed ID: 22404134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p21-activated kinase inhibitors.
    Rudolph J; Crawford JJ; Hoeflich KP; Chernoff J
    Enzymes; 2013; 34 Pt. B():157-80. PubMed ID: 25034104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAK'n it in: identification of a selective PAK inhibitor.
    Bokoch GM
    Chem Biol; 2008 Apr; 15(4):305-6. PubMed ID: 18420134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecules that allosterically inhibit p21-activated kinase activity by binding to the regulatory p21-binding domain.
    Kim DJ; Choi CK; Lee CS; Park MH; Tian X; Kim ND; Lee KI; Choi JK; Ahn JH; Shin EY; Shin I; Kim EG
    Exp Mol Med; 2016 Apr; 48(4):e229. PubMed ID: 27126178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently.
    Viaud J; Peterson JR
    Mol Cancer Ther; 2009 Sep; 8(9):2559-65. PubMed ID: 19723886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A brain serine/threonine protein kinase activated by Cdc42 and Rac1.
    Manser E; Leung T; Salihuddin H; Zhao ZS; Lim L
    Nature; 1994 Jan; 367(6458):40-6. PubMed ID: 8107774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of p21-activated kinases (PAKs).
    Rudolph J; Crawford JJ; Hoeflich KP; Wang W
    J Med Chem; 2015 Jan; 58(1):111-29. PubMed ID: 25415869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases.
    Cox KJ; Shomin CD; Ghosh I
    Future Med Chem; 2011 Jan; 3(1):29-43. PubMed ID: 21428824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.
    Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ
    ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-Guided Design of Group I Selective p21-Activated Kinase Inhibitors.
    Crawford JJ; Lee W; Aliagas I; Mathieu S; Hoeflich KP; Zhou W; Wang W; Rouge L; Murray L; La H; Liu N; Fan PW; Cheong J; Heise CE; Ramaswamy S; Mintzer R; Liu Y; Chao Q; Rudolph J
    J Med Chem; 2015 Jun; 58(12):5121-36. PubMed ID: 26030457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p21-activated kinase 4: a druggable target in the elusive oncogenic KRAS pathway?
    Azmi AS; Mohammad RM
    Future Med Chem; 2015; 7(1):5-7. PubMed ID: 25582328
    [No Abstract]   [Full Text] [Related]  

  • 14. Oncogenic Dbl, Cdc42, and p21-activated kinase form a ternary signaling intermediate through the minimum interactive domains.
    Wang L; Zhu K; Zheng Y
    Biochemistry; 2004 Nov; 43(46):14584-93. PubMed ID: 15544329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical inhibition through conformational stabilization of Rho GTPase effectors.
    Deacon SW; Peterson JR
    Handb Exp Pharmacol; 2008; (186):431-60. PubMed ID: 18491063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase.
    Porchia LM; Guerra M; Wang YC; Zhang Y; Espinosa AV; Shinohara M; Kulp SK; Kirschner LS; Saji M; Chen CS; Ringel MD
    Mol Pharmacol; 2007 Nov; 72(5):1124-31. PubMed ID: 17673571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphorylation of RhoGDI by p21-activated kinase 1.
    DerMardirossian CM; Bokoch GM
    Methods Enzymol; 2006; 406():80-90. PubMed ID: 16472651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virtual screening filters for the design of type II p38 MAP kinase inhibitors: a fragment based library generation approach.
    Badrinarayan P; Sastry GN
    J Mol Graph Model; 2012 Apr; 34():89-100. PubMed ID: 22306417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational insight into p21-activated kinase 4 inhibition: a combined ligand- and structure-based approach.
    Li RJ; Wang J; Xu Z; Huang WX; Li J; Jin SF; Zhao DM; Cheng MS
    ChemMedChem; 2014 May; 9(5):1012-22. PubMed ID: 24643945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of activation of Pak1 kinase by membrane localization.
    Lu W; Mayer BJ
    Oncogene; 1999 Jan; 18(3):797-806. PubMed ID: 9989831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.